文献速递心脏核医学肿瘤 PET/CT放射性药物与辐射防护

心脏肿瘤学中的分子影像生物标志物:成熟技术与未来展望

Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future Perspectives.
PubMed 文献 · J Nucl Med · 2023-01-01

本文综述心脏肿瘤学中分子影像生物标志物的应用,涵盖治疗前风险评估、早期检出与鉴别诊断心脏毒性并发症。文章指出平衡法放射性核素血管造影与心肌灌注显像为现有多学科指南鼓励的技术,而123I-间碘苄胍SPECT、18F-FDG与生长抑素受体PET、68Ga-成纤维细胞激活蛋白抑制剂PET及线粒体功能PET等新型模态可能更早检出心脏毒性征象。

要点

  • 分子影像生物标志物可辅助治疗前心脏肿瘤学评估、个体化监测及心脏毒性并发症的检出与鉴别诊断。
  • 现有指南鼓励平衡法放射性核素血管造影评估心室功能与心腔形态,心肌灌注显像用于额外检测缺血。
  • 123I-间碘苄胍SPECT、18F-FDG与生长抑素受体PET、68Ga-成纤维细胞激活蛋白抑制剂PET等新型模态可能检出更早的心脏毒性征象。

核心结论

  • 分子影像生物标志物可辅助治疗前心脏肿瘤学评估以实现一级预防和个体化监测,并用于心脏毒性并发症的检出与鉴别诊断。
  • 分子影像相比常规诊断的潜在优势包括对心脏稳态细微变化的检出敏感性更高、可重复性更高和观察者依赖性更低。
  • 高灵敏度的PET/MRI混合显像可能特别适合早期诊断。
  • 线粒体功能PET显像近期已在临床前模型中引入,将可能通过更高的敏感性和特异性以及实现更高程度的诊断概念个体化来拓宽应用领域。

研究设计与样本

  • 本文为综述,围绕心脏肿瘤学中已建立的分子影像技术与未来前景进行论述。

主要发现

  • 心脏毒性临床表现谱广,从细微且通常无症状的异常到严重的急性或慢性并发症,典型表现包括急性和慢性心力衰竭、心肌炎和心包炎、心律失常、缺血及内皮损伤。
  • 心脏毒性可与几乎所有当前癌症治疗相关,包括细胞毒性化疗、靶向治疗、免疫治疗、激素治疗和放疗。
  • 当前多学科指南鼓励的技术包括平衡法放射性核素血管造影用于评估心室功能和心腔形态,以及心肌灌注显像用于额外检测缺血。
  • 可能检出更早心脏毒性征象的新型模态包括123I-间碘苄胍SPECT显示交感神经支配、18F-FDG与生长抑素受体(68Ga-DOTATOC/DOTATATE)PET提示代谢转变和炎症、68Ga-成纤维细胞激活蛋白抑制剂PET监测心脏重构。

临床怎么用

  • 分子影像生物标志物可用于治疗前心脏肿瘤学评估以进行一级预防和个体化监测。
  • 分子影像生物标志物可用于心脏毒性并发症的检出和鉴别诊断。
  • 当前多学科指南鼓励使用平衡法放射性核素血管造影评估心室功能和心腔形态。
  • 当前多学科指南鼓励使用心肌灌注显像额外检测缺血。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel therapeutic options have significantly improved survival and long-term outcomes in many cancer entities. Unfortunately, this improvement in outcome is often accompanied by new and increasingly relevant therapy-related cardiovascular toxicity. In this context, cardiooncology has emerged as a new field of interdisciplinary individual patient care. Important tasks are pretherapeutic risk stratification and early detection and treatment of cardiotoxicity, which comprises cardiac damage in relation to cardiovascular comorbidities, the tumor disease, and cancer treatment. Clinical manifestations can cover a broad spectrum, ranging from subtle and usually asymptomatic abnormalities to serious acute or chronic complications. Typical manifestations include acute and chronic heart failure, myo- and pericarditis, arrythmias, ischemia, and endothelial damage. They can be related to almost all current cancer treatments, including cytotoxic chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and radiotherapy. Molecular imaging biomarkers can aid in pretherapeutic cardiooncologic assessment for primary prevention and personalized surveillance, detection, and differential diagnosis of cardiotoxic complications. Potential advantages over conventional diagnostics are the higher detection sensitivity for subtle changes in cardiac homeostasis, higher reproducibility, and better observer independence. Hybrid imaging with highly sensitive PET/MRI may be particularly suited for early diagnosis. Important technologies that are encouraged in current multidisciplinary guidelines are equilibrium radionuclide angiography for evaluation of ventricular function and chamber morphology, as well as myocardial perfusion imaging for additional detection of ischemia. Novel modalities that may detect even earlier signs of cardiotoxicity comprise 123I-metaiodobenzylguanidine SPECT to visualize sympathetic innervation, 18F-FDG and somatostatin receptor (68Ga-DOTATOC/DOTATATE) PET to indicate a metabolic shift and inflammation, and 68Ga-fibroblast activation protein inhibitor PET to monitor cardiac remodeling. In addition, PET imaging of mitochondrial function has recently been introduced in preclinical models and will potentially broaden the field of application through higher sensitivity and specificity and by enabling higher individualization of diagnostic concepts.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kersting D, Mavroeidi IA, Settelmeier S, et al. Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future Perspectives. J Nucl Med. 2023. PMID: 37918843. doi:10.2967/jnumed.122.264868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。